logo
US stocks edge higher ahead of a busy week of profit reports

US stocks edge higher ahead of a busy week of profit reports

Chicago Tribune21-07-2025
NEW YORK — U.S. stocks are edging higher ahead of a week full of profit updates from big U.S. companies, which Wall Street expects to keep growing despite pressure from President Donald Trump's tariffs. The S&P 500 was up 0.2% in early trading Monday and slightly above the all-time high it set on Thursday. The Dow Jones Industrial Average was up 86 points, or 0.2%, and the Nasdaq composite was adding 0.4% to its own record. Verizon Communications rose after reporting stronger profits and revenue for the latest quarter than analysts expected. Treasury yields eased in the bond market.Wall Street was poised to open with gains Monday ahead of a busy week of corporate earnings reports.
Futures for the S&P 500, the Dow Jones Industrial Average and Nasdaq were all up more than 0.2% before the bell.
Markets have stabilized since spring, when President Donald Trump's tariff announcements and pullbacks sent markets swinging wildly from day-to-day and sometimes hour-to-hour.
Trump pushed back the deadline for most countries to negotiate on tariffs to Aug. 1, which along with stronger-than-expected earnings reports, has helped to lift markets to record levels in recent weeks.
Domino's Pizza jumped 5.2% in premarket trading Monday after posting strong same-store sales in the U.S., even though the pizza chain just missed Wall Street's sales and profit targets.
Verizon climbed 4.6% after the phone and broadband giant beat analysts' sales and profit targets and raised its full-year guidance.
Other companies reporting this week include General Motors, Coca-Cola, Tesla and Google parent Alphabet.
This week also will bring updates on U.S. home sales, jobless claims and manufacturing.
Bitcoin rose more than 1% to more than $118,500 early Monday, just off all-time highs. Trump on Friday signed into law the GENIUS Act, which sets initial guardrails and consumer protections for stablecoins, a type of cryptocurrency that is tied to assets like the U.S. dollar to reduce volatility.
Elsewhere, in Europe at midday, Germany's DAX edged 0.1% lower, while the CAC 40 in Paris slipped 0.4%. Britain's FTSE 100 was essentially flat.
Markets were closed for a holiday in Japan, where the ruling Liberal Democrats have lost their coalition majorities in both houses of parliament for the first time since 1955 following Sunday's upper house election and the loss of their lower house majority in October.
A grim Prime Minister Shigeru Ishiba has vowed to stay on after the drubbing by voters frustrated over rising prices and political instability. Analysts said they expect his weakened government to crank up spending, adding to Japan's huge debt burden.
Japan is also facing the imposition of 25% tariffs across the board on its exports to the U.S. as talks with the Trump administration appear to have made little headway.
'We expect short-term political instability to intensify due to the difficulties of forming a majority coalition, a likely change in leadership, and a potential deadlock in trade negotiations,' Peter Hoflich of BMI, a part of the Fitch Group, said in a commentary.
'Without a structural reset through snap elections, Japan is likely to face prolonged policy drift throughout 2026,' he said.
Chinese shares advanced after the central bank kept its key 1-year and 5-year loan prime interest rates unchanged. Hong Kong's Hang Seng rose 0.7% to 24,994.14, while the Shanghai Composite index gained 0.7% to 3,559.79.
Recent improved economic data have eased pressure on the Chinese leadership to soften credit. Meanwhile, President Donald Trump's administration has softened its criticism of Beijing, raising hopes that the two sides can work out a trade deal and avert the imposition of sharply higher tariffs on imports from China.
South Korea's Kospi picked up 0.7% to 3,210.81 after the government reported a slight improvement in exports in June.
In Australia, the S&P/ASX 200 shed 1% to 8,668.20, while Taiwan's Taiex dropped 0.2%. In India, the Sensex rose 0.3%. Bangkok's SET gained 0.2%.
In other trading early Monday, U.S. benchmark crude oil reversed gains, leaving it essentially unchanged at $66.05 per barrel. Brent crude, the international standard, lost 8 cents to $69.20 per barrel.
The U.S. dollar fell to 147.55 Japanese yen from 147.98 yen. The euro climbed to $1.1667 from $1.1629.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ex-Treasury Secretary Calls Trump Worse Than Nixon After Jobs Report Tantrum
Ex-Treasury Secretary Calls Trump Worse Than Nixon After Jobs Report Tantrum

Yahoo

timea few seconds ago

  • Yahoo

Ex-Treasury Secretary Calls Trump Worse Than Nixon After Jobs Report Tantrum

President Donald Trump's inability to face the facts is yet another sign he's tilting towards tyranny, according to one former White House Cabinet member. After the release of a weak July jobs report and dismal updates to May and June numbers on Friday, a furious Trump sacked the top official at the Bureau of Labor Statistics in a post on Truth Social. 'The Economy is BOOMING under 'TRUMP,'' he declared while accusing BLS Commissioner Dr. Erika McEntarfer and her agency of manipulating employment statistics 'for political purposes.' Following McEntarfer's unceremonious ouster, Larry Summers, the treasury secretary under former President Bill Clinton, warned that Trump's actions are a dire sign for democracy when he appeared on the Sunday episode of ABC's 'This Week.' 'This is way beyond anything that Richard Nixon ever did,' Summers told host George Stephanopoulos. It's 'preposterous' for Trump to accuse the Bureau of Labor Statistics of warping employment numbers for political gain, Summers said, explaining that jobs data is meticulously calculated by hundreds of experts following rigorous formulas. Alarmed that the president would act like the figures were anything but objective, Summers told Stephanopoulos, 'This is the stuff of democracies giving way to authoritarianism.' Offering several more examples of Trump's autocratic impulses, he added, 'Firing statisticians goes with threatening the heads of newspapers, it goes with launching assaults on universities, it goes with launching assaults on law firms that defend clients that the elected boss finds uncongenial. This is really scary stuff.' Trump's labor report tantrum follows his decision to sue Wall Street Journal reporters and the paper's owner, Rupert Murdoch, over reports detailing his alleged connections to convicted sex offender Jeffrey Epstein. He also appeared to strong-arm television giant Paramount into a $16 million settlement just as it was seeking federal approval for a major merger with Skydance Media. The president successfully threatened to strip billions in funding from universities to drop their diversity, equity and inclusion policies while also accusing the institutions of failing to address antisemitism on campus. Before that, Trump pressured nine of the nation's top legal outfits into providing a collective $1 billion in pro bono services to avoid retaliation for their connections to federal prosecutors who oversaw investigations related to his first impeachment and the criminal investigations into Trump supporters' Jan. 6, 2021, attack on the U.S. Capitol. To Summers, the legal free-for-all and the tumult of Trump's ongoing tariff announcements seem like a recipe for economic instability. 'Who knows what business is going to be attacked next? Who knows what the rules are going to be?' he said. 'In an environment like that, what should a business do? It should sit, and it should wait.' Related... Trump Fires Labor Statistics Head In Meltdown Over Grim Jobs Report Senate Heads Home With No Deal On Nominations As Irate Trump Tells Schumer 'Go To Hell' It's Trump's Economy Now — And The Latest Financial Numbers Offer Some Warning Signs

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Yahoo

timea few seconds ago

  • Yahoo

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Business Wire

time2 minutes ago

  • Business Wire

LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lineage, Inc. ('Lineage' or 'the Company') (NASDAQ: LINE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ('IPO') conducted in July 2024, are encouraged to contact the firm before September 30, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Lineage suffered a weakening of demand as customers destocked excessive inventory and adjusted their businesses to changing consumer trends. The Company raised prices leading up to the IPO in an unsustainable manner. The Company failed to counteract its demand problems through marketing or its supposed competitive advantages. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Lineage, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store